METHODS
• This Phase IV, prospective, cross-sectional, non-randomized, non-interventional, multi-site (n=10) study was designed to evaluate score distribution, floor and ceiling effects, and inter-item correlations of the PSPQ, CSPQ, and mCSPQ for the ECHO -dobutamine sub-group of patients and clinicians.
• Additionally, internal consistency reliability was conducted where the number of items in a given domain was greater than 2 (e.g., summary scores and multi-item domain scores).
• In this institutional review board-approved study, clinicians and patients provided consent to participate and met the following criteria:
− Patient inclusion criteria were male or female ≥18 years old; had undergone a pharmacological stress SPECT MPI or stress ECHO; fluent in US English; and had internet access.
− Patients were excluded if there were significant physical or mental illness present; contraindications to pharmacologic tests; known allergies to pharmacologic stress agents; or had already completed a satisfaction questionnaire as part of this study.
− Clinician inclusion criteria were >2 years' experience performing, aiding, or monitoring pharmacological stress for SPECT MPI; fluent in US English; affiliated with a medical site that reported use of at least 1 stress agent; and were clinicians managing study patients.
• Patients completed a demographic and medical information form, underwent a pharmacological stress test (SPECT MPI or stress ECHO), and completed the PSPQ assessing PSA satisfaction and PSQ assessing satisfaction with the site (for construct validity) within 24 h of their stress test.
• Clinicians completed the CSPQ (for physicians) or mCSPQ (for nurses and technologists) for each of the stress agents within 2 weeks of study initiation and of the end of the study.
• A priori analyses outlined in the statistical analysis plan were executed to describe the measurement properties and score performance of the primary questionnaires (score distributions, reliability, and inter-item correlations) for the subsample of patients and clinicians who received or administered dobutamine for an ECHO procedure.
RESULTS
• The dobutamine subsample that was used for this analysis came from 4 of the 10 participating sites and consisted of 6 physicians who completed the CSPQ, 14 nurses/technologists who completed the mCSPQ, and 95 patients who completed the PSPQ and PSQ.
Psychometric analysis
• Score distributions for the items and domains within the CSPQ, mCSPQ, PSPQ, and PSQ showed variability on the scores from the items within each of the 4 questionnaires (and some evidence of ceiling and floor effects); patients and clinicians used the range of responses available to them and did so in ways consistent with their procedure experiences.
• For PSPQ, floor effects for the "preparation" and "reaction to agent" domains were >40%. Ceiling effects for "administration" "effects" and "overall satisfaction" domains were also >40%, which implied high levels of satisfaction in these areas ( Table 1 ).
• The diagnosis and assessment of cardiovascular disease is commonly conducted using single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), which is a non-invasive imaging method. 1 • SPECT MPI can be performed with cardiac stress induced by either exercise or a pharmacological stress agent (PSA) including regadenoson, adenosine, or dipyridamole.
• Pharmacological stress is an appropriate alternative to direct exercise for patients who are unable to exercise due to physical limitations.
• Another imaging technique is the stress echocardiography (ECHO) procedure, which utilizes sound wave pulses to visualize cardiovascular wall activity.
• Similar to the SPECT MPI, the stress ECHO can use either direct exercise or a PSA. The most commonly used PSA for stress ECHO is dobutamine.
• Given the variety of PSAs available to patients, researchers developed a set of clinical outcome assessment (COA) tools to measure patient and clinician satisfaction with and preference for drugs that induce cardiovascular stress, and patient satisfaction with services experienced at the site where the stress procedure was performed. These measures include:
− Patient Satisfaction and Preference Questionnaire (PSPQ) -an 8-item, self-report measure of a patient's satisfaction with and preference for drugs that induce cardiovascular stress during a cardiac nuclear stress test. Three items assess subject-rated bother with avoiding certain behaviour before testing, 2 assess the extent to which subjects experienced "stinging at injection site" and "nervousness while receiving the injection", and 3 assess subject-rated satisfaction with the procedure. An optional ninth item used to assess subject preference among PSAs was not included in this study because patients were exposed to only 1 PSA.
− Patient Satisfaction Questionnaire (PSQ) -a 17-item, self-report measure of a patient's satisfaction with the services experienced at the site where the stress procedure was performed. Five items assess satisfaction with the site, 6 assess satisfaction with the site staff, and 3 assessed overall satisfaction. The final 3 items of the PSQ are open-text-response questions that were not included in this evaluation.
− Clinician Satisfaction and Preference Questionnaire (CSPQ) -an 8-item, self-report measure designed to assess physicians' satisfaction with administering a PSA during a SPECT MPI or stress ECHO procedure. Seven items assess specific aspects associated with the agent and 1 assesses overall satisfaction.
− Modified Clinician Satisfaction and Preference Questionnaire (mCSPQ) -a 7-item version of the CSPQ developed for nurses or technologists (eliminates an item associated with image quality).
• Previous work documented psychometric properties of these COAs to assess satisfaction with PSAs used with SPECT MPI. Median (Q1, Q3) 0.00 (0.00, 0.00) 0.00 (0.00, 2.00) 9.00 (7.00, 10.00) 9.00 (5.00, 10.00) 9.00 (5.00, 10.00) Minimummaximum 0.00-8.00 0.00-9.00 3.00-10.00 1.00-10.00 1.00-10.00
Missing n (%) 48 ( Scale. † The preparation domain score is a weighted mean of PSPQ Items 1-3 that ranges from 0 to 10, where a higher score represents a higher level of bother. ‡ The reaction to agent domain score is a weighted mean of PSPQ Items 4 and 5 that ranges from 0 to 10, where a higher score represents a more extreme sensation with the reaction to the agent. § The administration domain score is the response to PSPQ Item 6 and ranges from 0 to 10, where a higher score represents a higher level of satisfaction with the administration.**The effects domain score is a weighted mean of PSPQ Item 7 and ranges from 0 to 10, where a higher score represents a higher level of satisfaction with the effects of the agent. † † The overall satisfaction domain score is the response to PSPQ Item 8 and ranges from 0 to 10, where a higher score represents a higher level of overall satisfaction. ‡ ‡ If ≥25% of patients endorsed a response of 0 for a particular item, a floor effect was noted. § § If ≥25% of patients endorsed a response of 10 for a particular item, a ceiling effect was noted.
• For CSPQ, ceiling effects for "image quality" was 33.3% ( Table 2) . Scale, where a higher score indicates a higher level of satisfaction. † The preparation domain score is a weighted mean of CSPQ Items 1 and 2 that ranges from 5 to 5, as well as a "not applicable" option, where 5 indicates "extremely dissatisfied," 0 indicates "neither satisfied nor dissatisfied," and 5 indicates "extremely satisfied" with the preparation. ‡ The administration domain score is a weighted mean of CSPQ Items 3 and 4 that ranges from 5 to 5, as well as a "not applicable" option, where 5 indicates "extremely dissatisfied," 0 indicates "neither satisfied nor dissatisfied," and 5 indicates "extremely satisfied" with the administration. § The monitor domain score is a weighted mean of CSPQ Item 5 that ranges from 5 to 5, as well as a "not applicable" option, where 5 indicates "extremely dissatisfied," 0 indicates "neither satisfied nor dissatisfied," and 5 indicates "extremely satisfied" with time to monitor the patient. **The side effects domain score is a weighted mean of CSPQ Item 6 that ranges from 5 to 5, as well as a "not applicable" option, where 5 indicates "extremely dissatisfied," 0 indicates "neither satisfied nor dissatisfied," and 5 indicates "extremely satisfied" with the side effects. † † The image quality domain score is a weighted mean of CSPQ Item 7 that ranges from 5 to 5, as well as a "not applicable" option, where 5 indicates "extremely dissatisfied," 0 indicates "neither satisfied nor dissatisfied," and 5 indicates "extremely satisfied" with the image quality. ‡ ‡ The overall satisfaction domain score is a weighted mean of CSPQ Item 8 that ranges from 5 to 5, as well as a "not applicable" option, where 5 indicates "extremely dissatisfied," 0 indicates "neither satisfied nor dissatisfied," and 5 indicates "extremely satisfied" with the stress agent overall. § § If ≥25% of physicians endorsed a response of 5 for a particular item, a floor effect was noted. ***If ≥25% of physicians endorsed a response of 5 for a particular item, a ceiling effect was noted.
• Nurses/technologists used the range of the item scales, which resulted in a range of scores on each domain on the mCSPQ (Table 3) . *The mCSPQ is a 7-item measure administered after the SPECT MPI procedure. Item responses use an 11-point Numeric Rating Scale, where a higher score indicates a higher level of satisfaction. † The preparation domain score is a weighted mean of mCSPQ Items 1 and 2 that ranges from 5 to 5, as well as a "not applicable" option, where 5 indicates "extremely dissatisfied," 0 indicates "neither satisfied nor dissatisfied," and 5 indicates "extremely satisfied" with the preparation. ‡ The administration domain score is a weighted mean of mCSPQ Items 3 and 4 that ranges from 5 to 5, as well as a "not applicable" option, where 5 indicates "extremely dissatisfied," 0 indicates "neither satisfied nor dissatisfied," and 5 indicates "extremely satisfied" with the administration. § The monitor domain score is a weighted mean of mCSPQ Item 5 that ranges from 5 to 5, as well as a "not applicable" option, where 5 indicates "extremely dissatisfied," 0 indicates "neither satisfied nor dissatisfied," and 5 indicates "extremely satisfied" with time to monitor the patient. **The side effects domain score is a weighted mean of mCSPQ Item 6 that ranges from 5 to 5, as well as a "not applicable" option, where 5 indicates "extremely dissatisfied," 0 indicates "neither satisfied nor dissatisfied," and 5 indicates "extremely satisfied" with the side effects. † † The overall satisfaction domain score is a weighted mean of mCSPQ Item 7 that ranges from 5 to 5, as well as a "not applicable" option, where 5 indicates "extremely dissatisfied," 0 indicates "neither satisfied nor dissatisfied," and 5 indicates "extremely satisfied" overall. ‡ ‡ If ≥25% of nurses/technologists endorsed a response of 5 for a particular item, a floor effect was noted. § § If ≥25% of nurses/technologists endorsed a response of 5 for a particular item, a ceiling effect was noted.
• Cronbach's alpha (α) was computed for all multi-item domain scores to evaluate internal consistency reliability and were strong in most instances (CSPQ and mCSPQ preparation [α=0. • Inter-item correlations for PSPQ ranged from -0.01 to 0.96, which are small to strong (Table 4) ; CSPQ ranged from 0.09 to 1.00, which are small to strong (Table 5) ; mCSPQ ranged from 0.73 to 1.00, which are strong (Table 6) ; and PSQ ranged from 0.58 to 1.00, which are moderate to strong ( Table 7) . Table 4 . Spearman rank (r) and polychoric inter-items correlations for the PSPQ* 
Item definitions
Given instructions prior to stress-inducing drug injection, how bothered were you today by having to: 1r -Avoid caffeine. 2r -Avoid eating. 3r -Avoid medication Thinking about today's injection: 4r -How much stinging did you feel at the injection site while receiving it? 5r -How much nervousness did you feel while receiving the injection? 6 -How satisfied or dissatisfied were you with the length of time it took for the injection to be administered? 7 -After receiving the injection, how satisfied or dissatisfied were you by the effects you experienced? 8 -Overall, how satisfied or dissatisfied were you with the drug that was injected today? 
Construct validity
• Correlations were weak between all of the domains of the PSQ and the preparation and reaction domains of the PSPQ (-0.058 to -0.329), while moderate-to-strong correlations were found between all 3 domains of the PSQ and the overall satisfaction domain of the PSPQ (0.436 to 0.495), as expected. The 3 PSQ domains were moderately correlated with the administration, and effects domains (0.374 to 0.473).
CONCLUSIONS

